Squarepoint’s Ascendis Pharma A/S ASND Stock Holding History

Squarepoint’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,100	Closed	-$1.17M	–	4380
2026 Q1	$1.17M	Buy	5,100 +1,200	+31%	+$269K	﹤0.01%	2646
2025 Q4	$832K	Buy	+3,900	New	+$805K	﹤0.01%	2767

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Squarepoint's ASND Position: Q2 2026 in Review

Squarepoint opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 9,686 shares worth $2.58M. The stake represents ﹤0.01% of the portfolio and ranks #2135 among its holdings. This is a return to the name: Squarepoint previously reported a position in ASND as recently as Q4 2025.

Squarepoint first reported a position in ASND in Q1 2018 and has held it in 17 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Squarepoint held 9,686 shares of Ascendis Pharma A/S worth $2.58M as of Q2 2026.
Ascendis Pharma A/S was a new Squarepoint position in Q2 2026.
Ascendis Pharma A/S made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2135 holding.
Squarepoint first reported a position in Ascendis Pharma A/S in Q1 2018 and has held it in 17 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.